Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Precision Medicine Institute
Colleague Insights
Video Expert Opinion
Resource Library
Conferences
Tumor Boards
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Lung Cancer

Journal Scan / Research · April 12, 2022

Clinical Efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in KRAS-Mutated NSCLC With STK11, KEAP1, or TP53 Co-Mutations

Journal for immunotherapy of cancer

 

 Save  Recommend
 Share

Additional Info

Journal for immunotherapy of cancer
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
J Immunother Cancer 2022 Feb 01;10(2)1-12, HJ West, M McCleland, F Cappuzzo, M Reck, TS Mok, RM Jotte, M Nishio, E Kim, S Morris, W Zou, D Shames, M Das Thakur, G Shankar, MA Socinski

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated